The FDA is reviewing Mirati's KRAS-blocking lung cancer drug - but taking longer to do it
Source : https://www.statnews.com/2022/02/15/fda-mirati-kras-lung-cancer/
irati Therapeutics said Tuesday that U.S. regulators accepted an application for its KRAS-blocking lung cancer drug, but the review time will be longer than hoped. The Food and Drug Administration...
Resistance to mutant KRAS V12-induced senescence in a hTERT/Cdk4-immortalized normal human bronchial epithelial cell line - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35149086/
doi: 10.1016/j.yexcr.2022.113053. Online ahead of print. 1 Division of Host Defense Sciences, Dept. of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Japan. 2 Division of Host Defense Sciences,...
Conclusion/Relevance: These results indicate that a hTERT/Cdk4 -immortalized normal bronchial epithelial cell line is partially resistant to mutant KRASV12-induced senescence. This suggests that OIS does not efficiently suppress KRASV12-induced transformation in the context of the simultaneous occurrence of telomerase upregulation and...
Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35096591/
Approximately 20% of lung adenocarcinomas harbor KRAS mutations, an oncogene that drives tumorigenesis and has the ability to alter the immune system and the tumor immune microenvironment. While KRAS was...
Relevance: We aim to summarize the tumor heterogeneity of KRAS mutant lung cancers and its immune-regulatory role, to report the efficacy achieved with current immunotherapies, and to overview the therapeutic approaches targeting KRAS mutations besides KRAS G12C inhibitors.
Targeting RAS oncogenesis with SOS1 inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35101230/
RAS proteins play major roles in many human cancers, but programs to develop direct RAS inhibitors so far have only been successful for the oncogenic KRAS mutant G12C. As an...
Relevance: We summarize the current understanding of which combination partners may be most beneficial for patients with RAS driven tumors.
Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations
Source : https://www.sciencedirect.com/science/article/abs/pii/S0065230X2100066X?via=ihub
The RAS family of small GTPases are among the most frequently mutated oncogenes in human cancer. Approximately 20% of cancers harbor a RAS mutation, and > 150 different missense mutations...
Relevance: Continuing to examine the biochemical differences in each RAS-mutant protein will continue to provide additional breakthroughs in allele-specific therapeutic strategies.